Efficacy of leflunomide in the treatment of palindromic rheumatism.
|
| Abstract | OBJECTIVE: The goal of treatment in palindromic rheumatism (PR) is to control the attacks and prevent disease evolution to chronic arthritis. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including antimalarial and methotrexate cannot control attacks in all patients. METHODS: In this retrospective study, we assessed the efficacy of leflunomide in patients with PR who had an inadequate response to DMARDs. In this study, patients who had a diagnosis of PR and were treated with leflunomide because of active disease despite treatment with csDMARDs for at least 6 months were included. Remission was defined as no attacks for 3 months and prednisolone dose ≤5 mg/d. Leflunomide treatment failure was defined as failure to achieve remission, the need to add other DMARDs for controlling attacks and disease progression to chronic arthritis during treatment with leflunomide. RESULTS: Ten cases with active disease despite treatment with hydroxychloroquine and methotrexate and low-dose prednisolone treated with leflunomide were included in the study. During the 12.6 ± 7.5 months of treatment with leflunomide, the frequency of attacks significantly decreased. Complete and partial remission were achieved in 90% of patients. CONCLUSION: Our results indicate that leflunomide controls PR attacks and it might be a new option for patients with PR.
|
|---|---|
| Authors | Maryam Sadri, Kamal Esalatmanesh, Alireza Khabbazi |
| Journal | International journal of rheumatic diseases (Int J Rheum Dis) Vol. 25 Issue 8 Pg. 893-896 (Aug 2022) ISSN: 1756-185X [Electronic] England |
| PMID | 35666009 (Publication Type: Journal Article) |
| Copyright | © 2022 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!